Novavax, Inc., a biotechnology company that develops next-generation vaccines for serious infectious diseases, announced that it has closed an advance purchase agreement ( APA) with Gavi, the Vaccine Alliance (Gavi) for the supply of its recombinant protein-based COVID-19 vaccine candidate to the COVAX Facility. Under the APA, Novavax is expected to produce and distribute 350…
Novavax, a biotechnology company developing next-generation vaccines for serious infectious diseases, announced the promotion of Gale E. Smith, Ph.D., to Senior Vice President, Discovery and Pre-Clinical Research and Chief Scientist, and the appointment of Troy Morgan as Senior Vice President, Chief Compliance Officer. The company also announced that Greg Covino will be stepping down as…
Novavax, a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced an amendment to its existing agreement with Serum Institute of India Private Limited (SIIPL) under which SIIPL will also manufacture the antigen component of NVX‑CoV2373, Novavax’ COVID‑19 vaccine candidate. With this agreement, Novavax increases its manufacturing capacity of NVX-CoV2373 to over two…
Novavax Inc, a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced the acquisition of Praha Vaccines, a part of the Cyrus Poonawalla Group, in an all cash transaction of approximately $167 million. The acquisition includes a biologics manufacturing facility and associated assets in Bohumil, Czech Republic. The facility is expected to provide…